Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian F Hermans

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Chemmedchem|May 14, 2020
The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides AttachedRinu Shrestha, Emma V Petley, Kathryn J Farrand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2012
Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for gliomaMartin K Hunn, Kathryn J Farrand, Kate W R Broadley, et al.
Immunotherapy|April 23, 2020
Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphomaCarole Grasso, Cameron S Field, Ching-Wen Tang, et al.
Chemical Communications (Cambridge, England)|July 16, 2011
Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imagingDavid A J Herman, Peter Ferguson, Soshan Cheong, et al.
Journal of Neuro-Oncology|November 5, 2014
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiformeMartin K Hunn, Evelyn Bauer, Catherine E Wood, et al.
BMJ Open|February 12, 2020
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)Philip George, Nathaniel Dasyam, Giulia Giunti, et al.
ACS Chemical Biology|June 3, 2024
A Glycolipid-Peptide-Hapten Tricomponent Conjugate Vaccine Generates Durable Antihapten Antibody Responses in MiceTheresa E Pankhurst, Isabelle Montgomerie, Andrew Marshall, et al.
ACS Chemical Biology|January 8, 2020
The Chemical Synthesis, Stability, and Activity of MAIT Cell Prodrug Agonists That Access MR1 in Recycling EndosomesJoshua Lange, Regan J Anderson, Andrew J Marshall, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2017
Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic CellsMariolina Salio, Olivier Gasser, Claudia Gonzalez-Lopez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2009
Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapyNina Dickgreber, Patrizia Stoitzner, Yan Bai, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Chemmedchem|May 14, 2020
The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides AttachedRinu Shrestha, Emma V Petley, Kathryn J Farrand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2012
Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for gliomaMartin K Hunn, Kathryn J Farrand, Kate W R Broadley, et al.
Immunotherapy|April 23, 2020
Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphomaCarole Grasso, Cameron S Field, Ching-Wen Tang, et al.
Chemical Communications (Cambridge, England)|July 16, 2011
Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imagingDavid A J Herman, Peter Ferguson, Soshan Cheong, et al.
Journal of Neuro-Oncology|November 5, 2014
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiformeMartin K Hunn, Evelyn Bauer, Catherine E Wood, et al.
BMJ Open|February 12, 2020
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)Philip George, Nathaniel Dasyam, Giulia Giunti, et al.
ACS Chemical Biology|June 3, 2024
A Glycolipid-Peptide-Hapten Tricomponent Conjugate Vaccine Generates Durable Antihapten Antibody Responses in MiceTheresa E Pankhurst, Isabelle Montgomerie, Andrew Marshall, et al.
ACS Chemical Biology|January 8, 2020
The Chemical Synthesis, Stability, and Activity of MAIT Cell Prodrug Agonists That Access MR1 in Recycling EndosomesJoshua Lange, Regan J Anderson, Andrew J Marshall, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2017
Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic CellsMariolina Salio, Olivier Gasser, Claudia Gonzalez-Lopez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2009
Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapyNina Dickgreber, Patrizia Stoitzner, Yan Bai, et al.
Pageof 10